Juvenile myelomonocytic leukaemia remains an aggressive childhood myeloid neoplasm defined by excessive proliferation of monocytic and granulocytic lineages. Clinicians recognize that hyperactive RAS signaling underpins this disorder. However, the microenvironmental immune alterations continue to challenge investigators. Recent translational findings reveal that macrophage phagocytosis in JMML remains intact despite malignant clonal transformation. Consequently, these clonal phagocytes actively shape tissue inflammation and modulate disease pathology across hematopoietic niches.

Biological Basis of Macrophage Phagocytosis in JMML

Historically, oncologists assumed that leukemic transformation severely impairs innate immune defenses, especially the scavenger and engulfment capacity of monocytic cells. However, functional assays now disprove this assumption in juvenile myelomonocytic leukaemia. Researchers evaluated primary patient samples alongside murine models harboring the gain-of-function Ptpn11 D61Y mutation. Surprisingly, clonal macrophages derived from these leukemic progenitors did not lose their primary immunological activity. Instead, these cells robustly engulfed target pathogens and cellular debris in laboratory assays.

Furthermore, quantitative analyses confirmed that functional engulfment correlates directly with cellular maturation states. Macrophages that exhibited mature surface markers sustained higher internalization rates than immature blast counterparts. Therefore, leukemic monocytic cells are not merely inert bystanders accumulating in peripheral tissues. They represent functionally competent immune effectors that actively interact with surrounding tissue components. In addition, these macrophages express distinct pattern-recognition receptors, enabling them to clear targets while paradoxically sustaining chronic tissue inflammation.

PTPN11 Mutations and Pro-Inflammatory M1 Polarization

Genomic heterogeneity significantly dictates the clinical trajectory of juvenile myelomonocytic leukaemia. Interestingly, recent studies show that specific oncogenic drivers fundamentally reshape macrophage phenotype. Splenic tissue specimens obtained from patients harboring somatic PTPN11 mutations displayed marked enrichment of M1-like macrophages compared to KRAS-mutated specimens or healthy pediatric controls. Therefore, the specific molecular lesion profoundly influences local immune architecture.

Moreover, these PTPN11-mutated M1-like macrophages demonstrated heightened baseline activation alongside elevated production of inflammatory cytokines. Classical oncology frameworks often associate M1 polarization with antitumor surveillance. However, sustained M1 activation in JMML appears to generate a deleterious hyperinflammatory state. Consequently, this persistent inflammatory signaling facilitates extensive myeloid expansion, splenomegaly, and constitutional symptoms in affected infants. Furthermore, functional evaluations revealed that M1-skewed clonal macrophages exhibited the highest intrinsic engulfment rates among all tested subsets. In contrast, KRAS-mutated counterparts displayed a less pronounced pro-inflammatory polarization pattern. Hence, clinicians must appreciate that different RAS pathway mutations induce divergent immunological microenvironments.

Evaluating the Therapeutic Impact of CD47 Blockade

Malignant cells frequently evade phagocytic destruction by upregulating CD47, a transmembrane protein that delivers a potent antiphagocytic signal. When CD47 binds to signal regulatory protein alpha on macrophages, it triggers inhibitory downstream phosphatases that halt phagocytosis. Investigators identified significant CD47 overexpression across human and murine JMML cells, indicating an active mechanism of innate immune evasion.

Consequently, researchers sought to interrupt this protective axis by administering magrolimab, a monoclonal antibody directed against CD47. In vitro experimental platforms confirmed that blocking CD47 markedly augmented macrophage-mediated engulfment of leukemic targets. Furthermore, the presence of active M1-like macrophages enhanced this clearance effect. This observation suggested that innate effector cells stood primed to attack malignant clones once clinicians released the molecular brake. However, translated in vivo assays yielded more complicated results. While magrolimab monotherapy successfully reduced leukemic burden within the spleen, it failed to eliminate malignant cells residing in the central marrow space. Therefore, while targeting CD47 offers mechanistic promise, single-agent anti-CD47 strategies demonstrate substantial pharmacological and anatomical constraints that prevent complete disease eradication.

Organ-Specific Responses and Resistance in the Bone Marrow

The distinct therapeutic response observed between splenic tissue and bone marrow highlights critical differences in tissue microenvironments. In patient-derived xenograft models, CD47 inhibition mediated pronounced splenic cytoreduction, yet marrow blast counts remained virtually unchanged. Several anatomical factors likely drive this therapeutic resistance. First, the splenic red pulp contains dense networks of active phagocytes that immediately engage antibody-opsonized targets. In contrast, the bone marrow niche harbors specialized stromal components, protective extracellular matrix proteins, and distinct cytokines that shield leukemic stem cells from macrophage destruction.

Additionally, researchers investigated whether combining magrolimab with hypomethylating agents could overcome this marrow resistance. Clinicians frequently prescribe azacitidine to mitigate high-risk JMML, and prior adult acute leukemia studies hinted at synergistic cytotoxicity. Nonetheless, preclinical testing revealed no therapeutic synergy between magrolimab and azacitidine in JMML models. In fact, co-administration did not improve marrow clearance or prolong overall survival in xenografts. Consequently, these findings caution clinicians against assuming that combination strategies effective in adult myelodysplastic syndromes will automatically succeed in pediatric myeloproliferative disorders.

Clinical Implications for Pediatric Hematology Practice

These translational insights carry profound significance for pediatric hematologists managing children with aggressive myelomonocytic disorders. Because allogeneic hematopoietic stem cell transplantation remains the only established curative modality, clinicians urgently need efficacious bridging therapies. The demonstration that JMML macrophages maintain active phagocytosis confirms that the innate immune system retains operational machinery despite aggressive clonal evolution. However, the inability of CD47 blockade to deplete marrow disease indicates that anti-CD47 monotherapy cannot replace conventional cytoreductive protocols.

Furthermore, the identification of driver-specific macrophage polarization provides a rational framework for future biomarker development. Patients harboring PTPN11 mutations experience prominent pro-inflammatory cascades. This finding suggests that combining targeted cytokine inhibition with signal transduction inhibitors, such as MEK inhibitors, might offer superior disease control. Additionally, therapeutic developers must engineer novel immunotherapies capable of penetrating the protective marrow sanctuary. Ultimately, deciphering the dynamic crosstalk between macrophage polarization, immune checkpoints, and bone marrow stroma will guide more precise therapeutic interventions.

Frequently Asked Questions

How does macrophage phagocytosis in JMML differ between mutation subtypes?

Macrophage phagocytosis in JMML varies significantly depending on underlying driver mutations. Human and murine models demonstrate that PTPN11-mutated spleens harbor markedly higher levels of pro-inflammatory M1-like macrophages than KRAS-mutated specimens or healthy tissue. Because M1-polarized macrophages exhibit superior intrinsic engulfment machinery, PTPN11-driven cells demonstrate higher phagocytic capacity. Consequently, these phenotypic distinctions directly correlate with heightened cytokine release, prominent splenomegaly, and more aggressive systemic clinical features in affected pediatric patients.

Why did magrolimab fail to clear leukemic cells in the bone marrow?

Magrolimab successfully reduces leukemic infiltration in the spleen but fails in the bone marrow due to microenvironmental divergence. The bone marrow stroma provides protective niches rich in supportive extracellular matrix proteins, anti-apoptotic signals, and immunosuppressive cytokines. Additionally, marrow macrophages display altered functional activation compared to splenic red pulp macrophages. Therefore, even when magrolimab blocks the CD47 antiphagocytic signal, local niche factors preserve leukemic stem cell survival and blunt innate clearance mechanisms.

Does combining azacitidine with CD47 inhibition enhance JMML therapy?

Preclinical studies demonstrate that combining azacitidine with magrolimab does not provide synergistic benefit in JMML models. Although azacitidine remains a standard pretransplant cytoreductive agent and demonstrated synergy with CD47 blockade in adult myeloid malignancies, patient-derived xenografts showed no enhanced reduction of leukemic blasts in the marrow. Consequently, clinicians cannot extrapolate adult therapeutic synergies directly to pediatric myeloproliferative disorders, highlighting the urgent need for distinct, biology-specific combination regimens for juvenile leukemia.

Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Wang J et al. Phagocytosis activity is retained by JMML macrophages and increased by CD47 inhibition. Br J Haematol. 2026 Nov 09. doi: 10.1111/bjh.70871. PMID: 43001447.

Niemeyer CM, Flotho C. Juvenile myelomonocytic leukemia: who's the driver after all? Blood. 2019;133(10):1021-1031. doi:10.1182/blood-2018-11-844688.

Majeti R, Chao MP, Min Y, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286-299. doi:10.1016/j.cell.2009.05.045.